Ansbert Gadicke - Net Worth and Insider Trading
Ansbert Gadicke Net Worth
The estimated net worth of Ansbert Gadicke is at least $312 Million dollars as of 2024-05-16. Ansbert Gadicke is the Director, 10% Owner of Cullinan Therapeutics Inc and owns about 7,892,819 shares of Cullinan Therapeutics Inc (CGEM) stock worth over $211 Million. Ansbert Gadicke is the 10% Owner of Repare Therapeutics Inc and owns about 11,706,178 shares of Repare Therapeutics Inc (RPTX) stock worth over $42 Million. Ansbert Gadicke is also the Director of Verastem Inc and owns about 2,033,333 shares of Verastem Inc (VSTM) stock worth over $27 Million. Besides these, Ansbert Gadicke also holds Harpoon Therapeutics Inc (HARP) , TCR2 Therapeutics Inc (TCRR) , Rigel Pharmaceuticals Inc (RIGL) , Oncorus Inc (ONCR) . Details can be seen in Ansbert Gadicke's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ansbert Gadicke has not made any transactions after 2023-05-22 and currently still holds the listed stock(s).
Transaction Summary of Ansbert Gadicke
Ansbert Gadicke Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ansbert Gadicke owns 33 companies in total, including Oncorus Inc (ONCR) , Dyne Therapeutics Inc (DYN) , and AlloVir Inc (ALVR) among others .
Click here to see the complete history of Ansbert Gadicke’s form 4 insider trades.
Insider Ownership Summary of Ansbert Gadicke
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ONCR | Oncorus Inc | 2020-10-06 | 10 percent owner |
| DYN | Dyne Therapeutics Inc | 2020-09-16 | 10 percent owner |
| ALVR | AlloVir Inc | 2020-07-29 | director & 10 percent owner |
 | | 2020-07-23 | director & 10 percent owner |
| | 2021-07-12 | 10 percent owner |
| | 2023-05-22 | director & 10 percent owner |
| | 2019-02-12 | 10 percent owner |
| | 2017-10-04 | 10 percent owner |
| | 2011-11-18 | director & 10 percent owner |
| | 2016-06-09 | director |
| | 2016-03-02 | 10 percent owner |
| | 2015-10-14 | 10 percent owner |
| | 2014-04-22 | 10 percent owner |
| | 2014-03-10 | 10 percent owner |
| | 2013-05-30 | 10 percent owner |
| | 2013-07-24 | 10 percent owner |
| | 2011-02-02 | 10 percent owner |
| | 2012-08-11 | 10 percent owner |
| | 2012-02-01 | director |
| | 2011-10-27 | 10 percent owner |
| | 2010-12-14 | other: Former 10% Owner |
| | 2007-08-03 | other: See explanation below |
| | 2010-09-30 | 10 percent owner |
| | 2010-03-11 | 10 percent owner |
| | 2010-01-27 | 10 percent owner |
| | 2009-11-05 | 10 percent owner |
| | 2006-12-19 | 10 percent owner |
| | 2003-12-17 | 10 percent owner |
| | 2004-07-02 | 10 percent owner |
| | 2004-03-10 | 10 percent owner |
| | 2021-10-28 | 10 percent owner |
| | 2021-04-29 | 10 percent owner |
| | 2021-09-16 | director & 10 percent owner |
Ansbert Gadicke Latest Holdings Summary
Ansbert Gadicke currently owns a total of 7 stocks. Among these stocks, Ansbert Gadicke owns 7,892,819 shares of Cullinan Therapeutics Inc (CGEM) as of September 16, 2021, with a value of $211 Million and a weighting of 67.6%. Ansbert Gadicke owns 11,706,178 shares of Repare Therapeutics Inc (RPTX) as of July 12, 2021, with a value of $42 Million and a weighting of 13.4%. Ansbert Gadicke also owns 2,033,333 shares of Verastem Inc (VSTM) as of February 1, 2012, with a value of $27 Million and a weighting of 8.55%. The other 4 stocks Harpoon Therapeutics Inc (HARP) , TCR2 Therapeutics Inc (TCRR) , Rigel Pharmaceuticals Inc (RIGL) , Oncorus Inc (ONCR) have a combined weighting of 10.45% among all his current holdings.
Latest Holdings of Ansbert Gadicke
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics Inc | 2021-09-16 | 7,892,819 | 26.72 | 210,896,124 |
| RPTX | Repare Therapeutics Inc | 2021-07-12 | 11,706,178 | 3.57 | 41,791,055 |
| VSTM | Verastem Inc | 2012-02-01 | 2,033,333 | 13.12 | 26,677,329 |
| HARP | Harpoon Therapeutics Inc | 2019-02-12 | 842,285 | 23.01 | 19,380,978 |
| TCRR | TCR2 Therapeutics Inc | 2023-05-22 | 7,529,946 | 1.48 | 11,144,320 |
| RIGL | Rigel Pharmaceuticals Inc | 2004-07-02 | 1,833,597 | 0.97 | 1,777,489 |
| ONCR | Oncorus Inc | 2020-10-06 | 2,377,025 | 0.13 | 299,505 |
Holding Weightings of Ansbert Gadicke
Ansbert Gadicke Form 4 Trading Tracker
According to the SEC Form 4 filings, Ansbert Gadicke has made a total of 9 transactions in Cullinan Therapeutics Inc (CGEM) over the past 5 years, including 1 buys and 8 sells. The most-recent trade in Cullinan Therapeutics Inc is the sale of 3,556 shares on September 16, 2021, which brought Ansbert Gadicke around $103,337.
According to the SEC Form 4 filings, Ansbert Gadicke has made a total of 9 transactions in Repare Therapeutics Inc (RPTX) over the past 5 years, including 1 buys and 8 sells. The most-recent trade in Repare Therapeutics Inc is the sale of 62,079 shares on July 12, 2021, which brought Ansbert Gadicke around $2 Million.
According to the SEC Form 4 filings, Ansbert Gadicke has made a total of 0 transactions in Verastem Inc (VSTM) over the past 5 years. The most-recent trade in Verastem Inc is the acquisition of 100,000 shares on February 1, 2012, which cost Ansbert Gadicke around $1,000,000.
More details on Ansbert Gadicke's insider transactions can be found in the Insider Trading History of Ansbert Gadicke table.Insider Trading History of Ansbert Gadicke
- 1
Ansbert Gadicke Trading Performance
GuruFocus tracks the stock performance after each of Ansbert Gadicke's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ansbert Gadicke is 14.14%. GuruFocus also compares Ansbert Gadicke's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ansbert Gadicke within 3 months outperforms 1 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ansbert Gadicke's insider trading performs compared to the benchmark.
Performance of Ansbert Gadicke
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 7.47 | | | | | |
| Relative Return to S&P 500(%) | 4.37 | | | | | |
Ansbert Gadicke Ownership Network
Ansbert Gadicke Owned Company Details
What does Oncorus Inc do?
Who are the key executives at Oncorus Inc?
Ansbert Gadicke is the 10 percent owner of Oncorus Inc. Other key executives at Oncorus Inc include Interim CEO Brian J. Shea , Interim CFO Alexander Nolte , and director & 10 percent owner & other: *Possible Member of 10% Group James E Flynn .
Oncorus Inc (ONCR) Insider Trades Summary
Over the past 18 months, Ansbert Gadicke made no insider transaction in Oncorus Inc (ONCR). Other recent insider transactions involving Oncorus Inc (ONCR) include a net sale of 551,663 shares made by James E Flynn ,
In summary, during the past 3 months, insiders sold 0 shares of Oncorus Inc (ONCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 551,663 shares of Oncorus Inc (ONCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 551,663 shares.
Oncorus Inc (ONCR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Oncorus Inc Insider Transactions
Ansbert Gadicke Mailing Address
Above is the net worth, insider trading, and ownership report for Ansbert Gadicke. You might contact Ansbert Gadicke via mailing address: The John Hancock Tower, 200 Clarendon Street, 54th Floor, Boston Ma 02116.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
